Wikisage, the free encyclopedia of the second generation, is digital heritage

Rufinamide: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
mNo edit summary
Line 7: Line 7:
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf  Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]</ref>
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf  Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]</ref>
<gallery>File:Rufinamid.svg.png</gallery>
<gallery>File:Rufinamid.svg.png</gallery>
 
==Weblinks==


[http://flexikon.doccheck.com/de/Rufinamid FLexikon:Rufinamid]
[http://flexikon.doccheck.com/de/Rufinamid FLexikon:Rufinamid]


[http://www.pharmawiki.ch/wiki/index.php?wiki=Rufinamid Pharmawiki:Rufinamid]
<references/>
<references/>
{{Wikidata|Q408565}}
{{Wikidata|Q408565}}


[[Category:Anticonvulsants]]
[[Category:Anticonvulsants]]

Revision as of 00:25, 26 August 2017

Lennox-Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconclusive. Otsuka et al. (2014) state rufinamide as an efficacious and well tolerated AED [1](cf. Alssad et Coren 2014) [2]


"Rufinamide received the status of orphan drug for epilepsy in 2004 in Europe" [3]

Weblinks

FLexikon:Rufinamid

Pharmawiki:Rufinamid

Q408565 at Wikidata  Interwiki via Wikidata